GlassScriptPhysician profile
Laura Calma
NPI 1861129108
$1,230.90
in general payments reported to CMS, 2019-2025
12 companies · $624 in 2025
The $624 reported for 2025 was more than what 82% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $607 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,230.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $220.99 | 2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $215.30 | 2024-2025 | |
| Harrow Eye, LLC | $197.51 | 2024 | Iheezo |
| Glaukos Corporation | $195.92 | 2024-2025 | Ce-Marked Kxla System, Idosetr |
| Biotissue Holdings INC. | $153.17 | 2024-2025 | |
| Sight Sciences, INC. | $107.25 | 2024 | Tearcare System |
| Alcon Vision LLC | $45.55 | 2025 | Eysuvis |
| Abbvie INC. | $24.47 | 2024 | |
| Tearlab Corp | $22.62 | 2024 | Scoutpro Osmolarity System |
| Tarsus Pharmaceuticals, INC. | $18.29 | 2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $15.65 | 2024 | Miebo, Lotemax Sm, Vyzulta |
| Coopervision INC. | $14.18 | 2024 | Myday Contact Lens |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Calma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.